Preclinical (Uehara et al, 2003; Kim et al, 2006) and early clinical (Mathew et al, 2004) studies suggested a benefit for the combination of therapeutic inhibition of the platelet-derived growth factor receptor (PDGFR) and taxane chemotherapy for bone metastases from prostate cancer. The gene discussed is PDGFRB; the disease is prostate cancer.